Valve revolution: TAVR expands as next-gen tech gains steam

The regulatory arc for Edwards Lifesciences’ TAVR business shows how a therapy once confined to last-resort use moved steadily toward the center of valve care. On November 2, 2011, FDA approved Edwards Lifesciences' SAPIEN transcatheter heart valve for patients with symptomatic severe aortic stenosis who were considered inoperable, explicitly noting it “displac[ed] prior reliance on medical management or balloon valvuloplasty for these patients,” which positioned TAVR as a solution for the most extreme group rather than for lower-risk candidates.

By 2019, that narrow framing had been overtaken by a much broader one, with the FDA extending Edwards’s reach into patients who previously would have been steered toward surgery first. On August 16, 2019, the FDA approved Edwards’s SAPIEN 3 and SAPIEN 3 Ultra valves for “patients with severe symptomatic aortic stenosis at low risk for open-heart surgery,” explicitly displacing the prior practice that reserved TAVR mainly for inoperable or high-risk patients and marking its transition from rescue therapy to mainstream option.

October 2026 made the mechanism visible: regulatory clearances and favorable outcomes are no longer just validating transcatheter valve therapy, they are widening who can receive it and what procedures hospitals can offer. IndexBox said the market’s shift into broader use is “underpinned by robust clinical evidence” and by “favorable trial data and regulatory approvals,” while also noting that next-generation balloon-expandable and self-expanding valves are improving procedural outcomes and “driving adoption across diverse patient anatomies,” a direct link between better performance, broader eligibility, and faster uptake.

That clinical-regulatory expansion is already showing up in forecasts and approvals. IndexBox said, “The market is expected to grow at a compound annual growth rate (CAGR) of 8.2%, reaching a market index of 220 by 2035 (2025=100),” and added that “The baseline scenario… forecasts robust expansion from 2026 to 2035” as adoption broadens and delivery technology improves; the same October 2026 regulatory-approval context includes additional international approvals tied to cardiovascular intervention support, reinforcing a broader environment of regulatory momentum that can facilitate uptake, alongside the FDA approval of Edwards’ tricuspid valve repair device reported by RAPS.

The clearest sign of where next-generation transcatheter valves are headed comes from GrOwnValve’s first-in-human program, which is aimed not just at replacing diseased valves but at fixing the weaknesses that made earlier prostheses a poor fit for younger patients. In its GECT-DZHK28 study, the company said “All five patients complete six-month follow-up without predefined prosthesis-related safety events,” while explicitly framing the platform as a way “to address major limitations of conventional valve replacements, including structural valve deterioration, repeated interventions and the inability of current prostheses to accommodate patient growth.”

That design brief matters most in congenital heart disease, where the problem is often not a single successful procedure but the cascade of reinterventions that can follow as a child grows. GrOwnValve says its “long-term objective is to develop heart valves offering improved durability, biological integration and potentially the ability to adapt to patient growth,” and investigator Dr. Peter Kramer of the German Heart Center of Charité said that for patients “particularly those facing repeated valve interventions, a personalized valve made from their own tissue could represent an important advancement,” underscoring how device development is now targeting durability and growth together.